Brief: Korro Receives Australian HREC Approval and CTN Clearance
21/11/2024 12:35
Nov 21 (Reuters) - Korro Bio Inc KRRO.O :
* KORRO RECEIVES AUSTRALIAN HREC APPROVAL AND CTN CLEARANCE
TO
INITIATE PHASE 1/2A CLINICAL STUDY (REWRITE) OF KRRO-110 FOR
ALPHA-1 ANTITRYPSIN DEFICIENCY
* KORRO BIO INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1
2025
* KORRO BIO INC - INTERIM READOUT EXPECTED IN H2 2025, STUDY
COMPLETION IN 2026
Source text: ID:nGNX7bJg5F
Further company coverage: KRRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview